• Explore /
  • Poster
  • / Efficacy and safety of definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma.

Efficacy and safety of definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma.

Abstract Video & Slides Poster

Authors

null

Takumi Habu

National Cancer Center Hospital East, Kashiwa, Japan

Takumi Habu , Hideaki Bando , Ryosuke Kumanishi , Takatsugu Ogata , Takeshi Fujisawa , Shogo Kumagai , Hisashi Fujiwara , Saori Mishima , Daisuke Kotani , Masaki Nakamura , Hidehiro Hojo , Yusuke Yoda , Shohei Koyama , Hiroyoshi Nishikawa , Tomonori Yano , Takeo Fujita , Shigenori Kadowaki , Kei Muro , Takahiro Kinoshita , Takashi Kojima

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

DOI

10.1200/JCO.2022.40.4_suppl.252

Abstract #

252

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Motoo Nomura

First Author: Wencheng Zhang

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).

Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).

First Author: Changying Guo

First Author: Kazuomi Ueshima